Novai
Hashir Gill has a diverse work experience in various industries. Hashir started their career as a Research Intern at A*STAR - Agency for Science, Technology and Research in 2017. Hashir then worked as a Material Product Development Intern at Structo 3D in 2018. In 2019, they were an Undergraduate Research Assistant at the National University of Singapore, Faculty of Science, where they co-authored a research paper. Later that year, they joined Shimadzu (Asia Pacific) Pte Ltd as an Analytical Chemistry Consultant, providing support to pharmaceutical and F&B manufacturing clients.
In 2020, Hashir joined Insect Feed Technologies Pte Ltd as the Operations & Process Improvement Lead, where they led a bioprocess optimization project and secured a partnership with Klook SG. In 2021, they became a Founder in Residence at Entrepreneur First, where they analyzed FMCG consumer research market trends and identified a market entry opportunity in the alternative protein sector.
From 2021 to 2023, Hashir worked as a Business Development Associate at OrciTrials, where they performed LinkedIn outreach and created sales content to build client pipelines for clinical trial services. Hashir also created a list of companies on HubSpot CRM and used market research tools to identify prospects.
Currently, Hashir is working as a Business Development Associate at Novai, a British biotechnology start-up. Hashir'sresponsibilities include commercializing DARC Technology, an exploratory retinal biomarker for use in clinical studies for Age-related Macular Degeneration & glaucoma.
Hashir Gill completed their secondary education from 2014 to 2016 at Overseas Family School in Singapore, where they earned an IB Diploma. Hashir then pursued a Bachelor of Science (Honors) degree in Chemistry from 2016 to 2020 at the National University of Singapore.
This person is not in any teams
Novai
Novai is a British biotechnology start-up, commercialising DARC Technology, an exploratory retinal biomarker for use in Age-related Macular Degeneration (AMD) & glaucoma clinical studies. DARC combines an innovative patented biologic with a state-of-the-art AI algorithm and uses standard imaging equipment to identify cellular level diseaseactivity. DARC Technology can be used to measure the impact of current and future therapeutics and interventions by assessment of disease activity whilst identifying non-responders to existing and new interventions, resulting in the avoidance of costly, ineffective or un-required medical management. DARC helps to stratify patients in clinical trials, resulting in the creation of enriched patient cohorts, consisting of those at highest risk of rapid disease progression.DARC has been developed by Professor M Francesca Cordeiro at University College London through Wellcome Trust funding and is now approved as an exploratory biomarker by the FDA & MHRA. Following further analysis of Phase II data, several other indications may follow, including Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Diabetes Mellitus and Cancer.